Literature DB >> 11757453

[Safety margins in the excision of primary malignant melanoma. Proposals based on controlled clinical trials].

A Hauschild1, S Eiling, S Lischner, T C Haacke, E Christophers.   

Abstract

Excisional biopsy is recommended as the procedure of choice whenever there is suspicion of malignant melanoma. Incisional biopsies are only rarely indicated. For nearly seventy years the debate about the optimum resection safety margin around the primary tumor was influenced by historical case reports and paradigms. Recently, controlled clinical studies have provided new insights. Accumulating evidence over the last two decades shows that narrower surgical margins influence neither the rate of satellites or in-transit-metastases nor the occurrence of advanced metastatic disease. Local recurrence is rare (approx. 0.1%) when primary tumors are thin and is seen more often (approx. 10%) in primary tumors of greater thickness (> 4 mm). Analysis of the overall survival in randomized trials shows equal prognosis for malignant melanoma for narrow and wide resection margins. Due to these findings in-toto excisional biopsy for in-situ melanoma, a resection margin of 1 cm for thin primary tumors (< 1 cm tumor thickness) and a resection margin of 1 to 2 cm for primary tumors greater than 1 mm appears sufficient. With these recommendations, primary closure of wounds will be possible in nearly all cases, reducing surgical costs and morbidity. This article should serve as a basis of discussion for the proposed revision of the current guidelines of the German Dermatologic Society (DDG) on the primary surgical care of melanoma patients.

Entities:  

Mesh:

Year:  2001        PMID: 11757453     DOI: 10.1007/s001050170034

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  4 in total

1.  [Comment on the contribution by A. Hauschild et al.: "Safety margins in excision of primary malignant melanoma"].

Authors:  M Möhrle; H Breuninger
Journal:  Hautarzt       Date:  2002-04       Impact factor: 0.751

Review 2.  [Adjuvant therapy of melanoma. From non-specific immune stimulants into the future].

Authors:  A Hauschild; U R Kleeberg
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 3.  [Cutaneous malignant melanoma. Excision margins and lymph node dissections].

Authors:  G Sebastian
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

4.  Treatment of melanoma.

Authors:  Claus Garbe; Patrick Terheyden; Ulrich Keilholz; Oliver Kölbl; Axel Hauschild
Journal:  Dtsch Arztebl Int       Date:  2008-12-05       Impact factor: 5.594

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.